Dias I, Costa RGA,Rodrigues A, Silva SLR,Oliveira MS,Soares MBP,Dias RB, Valverde LF, Gurgel Rocha CA
Measurement of chronic oxidative and inflammatory stress by quantification of isoketal/levuglandin gamma-ketoaldehyde protein adducts using liquid chromatography tandem mass spectrometry
Semaglutide activates the GLP-1 pathway
186 The mechanism by which hyaluronic acid may protect elastin is not yet understood
Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy
Those who continued the medication maintained or continued to lose weight, while those who stopped regained much of the weight lost, underscoring the need for long-term therapy.23 Longer-term outcomes were assessed in STEP 5, which extended treatment to 104 weeks and demonstrated sustained weight loss of approximately 15%.24 In East Asian populations, STEP 6 showed similar results, with participants achieving an average 12% to 13% weight loss over 68 weeks.25 STEP 7, a 44-week trial including participants from China, Hong Kong, Brazil, and South Korea, found that those on semaglutide lost an average of 12.1% of their body weight compared with 3.6% with placebo.26 Lastly, STEP 8 compared semaglutide with liraglutide and showed greater efficacy with semaglutide (15.8% vs 6.4% weight loss), as well as better tolerability and more convenient weekly dosing.27 Taken together, the STEP trials show that semaglutide consistently results in clinically meaningful weight loss across various populations and treatment conditions
